Literature DB >> 24985755

Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy.

Filippo Montemurro1, Serena Di Cosimo2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24985755     DOI： 10.1016/j.breast.2014.06.007

Source DB:  PubMed          Journal:  Breast        ISSN： 0960-9776            Impact factor:   4.380


× No keyword cloud information.
  3 in total

Review 1.  Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors.

Authors:  Frank Rojas; Edwin Roger Parra; Ignacio Ivan Wistuba; Cara Haymaker; Luisa Maren Solis Soto
Journal:  Cancers (Basel)       Date:  2022-06-02       Impact factor: 6.575

2.  International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

Authors:  Vito Amoroso; Daniele Generali; Thomas Buchholz; Massimo Cristofanilli; Rebecca Pedersini; Giuseppe Curigliano; Maria Grazia Daidone; Serena Di Cosimo; Mitchell Dowsett; Stephen Fox; Adrian L Harris; Andreas Makris; Lucia Vassalli; Andrea Ravelli; Maria Rosa Cappelletti; Christos Hatzis; Clifford A Hudis; Paolo Pedrazzoli; Anna Sapino; Vladimir Semiglazov; Gunter Von Minckwitz; Edda L Simoncini; Michael A Jacobs; Peter Barry; Thorsten Kühn; Sarah Darby; Kerstin Hermelink; Fraser Symmans; Alessandra Gennari; Gaia Schiavon; Luigi Dogliotti; Alfredo Berruti; Alberto Bottini
Journal:  J Natl Cancer Inst Monogr       Date:  2015-05

Review 3.  A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future.

Authors:  Sijia Ren; Anyi Xu; Yilian Lin; D Ross Camidge; Massimo Di Maio; Raffaele Califano; Toyoaki Hida; Antonio Rossi; Nicolas Guibert; Chengchu Zhu; Jianfei Shen
Journal:  Transl Lung Cancer Res       Date:  2021-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.